Citi raised the firm’s price target on Guardant Health (GH) to $135 from $100 and keeps a Buy rating on the shares. The firm adjusted ratings and price targets in the life science tools and diagnostics group as part of its 2026 outlook. Citi continues to see a recovery in the bioprocessing and pharma markets.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health assumed with an Overweight at Morgan Stanley
- Private Markets: Prediction market platform Kalshi secures $300M
- Guardant Health price target raised to $120 from $90 at Piper Sandler
- Guardant Health Completes $402.5M Convertible Notes Offering
- Cathie Wood Buys the Dip in Pinterest (PINS), Sells Roku and Robinhood Stocks